Larissa I van der Windt (Larissa van der Windt)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 5

Top Topics

Pluripotent Stem Cells

Low Birth Weight

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Larissa I van der Windt, Job Klumper, Emilie V J van Limburg Stirum, Janneke van 't Hooft, Madelon van Wely, Aleid G van Wassenaer-Leemhuis, Eva Pajkrt, Martijn A Oudijk, null null
Atosiban versus placebo in the treatment of threatened preterm birth between 30 and 34 weeks gestation: study protocol of the 4-year APOSTEL 8 follow-up. BMJ open 14 (7) (2024)
Larissa I van der Windt, Job Klumper, Emilie V J van Limburg Stirum, Janneke van 't Hooft, Madelon van Wely, Aleid G van Wassenaer-Leemhuis, Eva Pajkrt, Martijn A Oudijk, null null
Atosiban versus placebo in the treatment of threatened preterm birth between 30 and 34 weeks gestation: study protocol of the 4-year APOSTEL 8 follow-up. BMJ open 14 (7) (2024)
Larissa I van der Windt, Job Klumper, Emilie V J van Limburg Stirum, Janneke van 't Hooft, Madelon van Wely, Aleid G van Wassenaer-Leemhuis, Eva Pajkrt, Martijn A Oudijk, null null
Atosiban versus placebo in the treatment of threatened preterm birth between 30 and 34 weeks gestation: study protocol of the 4-year APOSTEL 8 follow-up. BMJ open 14 (7) (2024)
Larissa I van der Windt, Job Klumper, Emilie V J van Limburg Stirum, Janneke van 't Hooft, Madelon van Wely, Aleid G van Wassenaer-Leemhuis, Eva Pajkrt, Martijn A Oudijk, null null
Atosiban versus placebo in the treatment of threatened preterm birth between 30 and 34 weeks gestation: study protocol of the 4-year APOSTEL 8 follow-up. BMJ open 14 (7) (2024)
Emilie V J van Limburg Stirum, Larissa I van der Windt, Charlotte E van Dijk, Anneloes L van Baar, Aleid G Leemhuis, Madelon van Wely, Marjon A de Boer, Janneke van 't Hooft, Martijn A Oudijk, Eva Pajkrt, null null
Pessary or progesterone to prevent preterm birth in women with short cervical length: protocol of the 4-6 year follow-up of a randomised controlled trial (Quadruple-P). BMJ open 12 (8) (2022)